Evidence map›Paper›PMID 36114428›Full record

ArticleDiabetologia2023

Serum sex hormone-binding globulin is a mediator of the association between intrahepatic lipid content and type 2 diabetes: the Maastricht Study.

Pomme I H G Simons, Olivier Valkenburg, Marjo P H van de Waarenburg, Marleen M J van Greevenbroek, M Eline Kooi, Jacobus F A Jansen, Casper G Schalkwijk, Coen D A Stehouwer, Martijn C G J Brouwers

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetologia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Pomme I H G SimonsDepartment of Internal Medicine, Division of Endocrinology and Metabolic Diseases, Maastricht University Medical Centre, Maastricht, the Netherlands.
Olivier ValkenburgDepartment of Reproductive Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands.
Marjo P H van de WaarenburgLaboratory for Metabolism and Vascular Medicine, Maastricht University, Maastricht, the Netherlands.
Marleen M J van GreevenbroekLaboratory for Metabolism and Vascular Medicine, Maastricht University, Maastricht, the Netherlands.
M Eline KooiCARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, the Netherlands.
Jacobus F A JansenDepartment of Radiology and Nuclear Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands.
Casper G SchalkwijkLaboratory for Metabolism and Vascular Medicine, Maastricht University, Maastricht, the Netherlands.
Coen D A StehouwerLaboratory for Metabolism and Vascular Medicine, Maastricht University, Maastricht, the Netherlands.
Martijn C G J BrouwersDepartment of Internal Medicine, Division of Endocrinology and Metabolic Diseases, Maastricht University Medical Centre, Maastricht, the Netherlands. mcgj.brouwers@mumc.nl.
Maastricht University · NLMaastricht University Medical Centre · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aims/hypothesisSerum sex hormone-binding globulin (SHBG) has been proposed to act as a hepatokine that contributes to the extrahepatic complications observed in non-alcoholic fatty liver disease (NAFLD). However, it remains uncertain whether serum SHBG mediates the association between intrahepatic lipids (IHL) and type 2 diabetes. Therefore, we studied whether, and to what extent, serum SHBG mediates the association between IHL content and type 2 diabetes.

methodsWe used cross-sectional data from the Maastricht Study (n=1554), a population-based cohort study with oversampling of individuals with type 2 diabetes. Type 2 diabetes status was assessed by oral glucose tolerance test, and IHL content was measured using 3T Dixon MRI. Mediation analyses were performed to assess the role of serum SHBG in mediating the association between IHL content and type 2 diabetes.

resultsIHL content was significantly associated with type 2 diabetes in women and men (OR 1.08 [95% CI 1.04, 1.14] and OR 1.12 [95% CI 1.08, 1.17], respectively). Serum SHBG significantly mediated the association between IHL content and type 2 diabetes. The contribution of serum SHBG was higher in women (OR 1.04 [95% CI 1.02, 1.07]; proportion mediated 50.9% [95% CI 26.7, 81.3]) than in men (OR 1.02 [95% CI 1.01, 1.03]; proportion mediated 17.2% [95% CI 9.6, 27.6]). Repeat analyses with proxies of type 2 diabetes and adjustment for covariates did not substantially affect the results. CONCLUSIONS/

interpretationIn this large-scale population-based cohort study, serum SHBG was found to be a mediator of the association between IHL content and type 2 diabetes. These findings extend our understanding of the potential mechanisms by which NAFLD is a risk factor for type 2 diabetes, and further elaborate on the role of SHBG as a hepatokine.

Indexed as

Diabetes Mellitus, Type 2LiverSex Hormone-Binding GlobulinCohort StudiesCross-Sectional StudiesFemaleHumansLipidsMaleLipidsSex Hormone-Binding GlobulinHepatokineMediationNon-alcoholic fatty liver diseaseSex hormone-binding globulinType 2 diabetes

Identifiers

PMID36114428
PMCPMC9729158
OpenAlexW4296163583

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.